AIM: To reveal the characteristics of CD133(+) cells in the liver. METHODS: This study examined the histological characteristics of CD133(+) cells in non-neoplastic and neoplastic liver tissues by immunostaining, and also analyzed the biological characteristics of CD133(+) cells derived from human hepatocellular carcinoma (HCC) or cholangiocarcinoma cell lines. RESULTS: Immunostaining revealed constant expression of CD133 in non-neoplastic and neoplastic biliary epithelium, and these cells had the immunophenotype CD133(+)/CK19(+)/HepPar-1(-). A small number of CD133(+)/CK19(-)/HepPar-1(+) cells were also identified in HCC and combined hepatocellular and cholangiocarcinoma. In addition, small ductal structures, resembling the canal of Hering, partly surrounded by hepatocytes were positive for CD133. CD133 expression was observed in three HCC (HuH7, PLC5 and HepG2) and two cholangiocarcinoma cell lines (HuCCT1 and CCKS1). Fluorescence-activated cell sorting (FACS) revealed that CD133(+) and CD133(-) cells derived from HuH7 and HuCCT1 cells similarly produced CD133(+) and CD133(-) cells during subculture. To examine the relationship between CD133(+) cells and the side population (SP) phenotype, FACS was performed using Hoechst 33342 and a monoclonal antibody against CD133. The ratios of CD133(+)/CD133(-) cells were almost identical in the SP and non-SP in HuH7. In addition, four different cellular populations (SP/CD133(+), SP/CD133(-), non-SP/CD133(+), and non-SP/CD133(-)) could similarly produce CD133(+) and CD133(-) cells during subculture. CONCLUSION: This study revealed that CD133 could be a biliary and progenitor cell marker in vivo. However, CD133 alone is not sufficient to detect tumor-initiating cells in cell lines.
AIM: To reveal the characteristics of CD133(+) cells in the liver. METHODS: This study examined the histological characteristics of CD133(+) cells in non-neoplastic and neoplastic liver tissues by immunostaining, and also analyzed the biological characteristics of CD133(+) cells derived from humanhepatocellular carcinoma (HCC) or cholangiocarcinoma cell lines. RESULTS: Immunostaining revealed constant expression of CD133 in non-neoplastic and neoplastic biliary epithelium, and these cells had the immunophenotype CD133(+)/CK19(+)/HepPar-1(-). A small number of CD133(+)/CK19(-)/HepPar-1(+) cells were also identified in HCC and combined hepatocellular and cholangiocarcinoma. In addition, small ductal structures, resembling the canal of Hering, partly surrounded by hepatocytes were positive for CD133. CD133 expression was observed in three HCC (HuH7, PLC5 and HepG2) and two cholangiocarcinoma cell lines (HuCCT1 and CCKS1). Fluorescence-activated cell sorting (FACS) revealed that CD133(+) and CD133(-) cells derived from HuH7 and HuCCT1 cells similarly produced CD133(+) and CD133(-) cells during subculture. To examine the relationship between CD133(+) cells and the side population (SP) phenotype, FACS was performed using Hoechst 33342 and a monoclonal antibody against CD133. The ratios of CD133(+)/CD133(-) cells were almost identical in the SP and non-SP in HuH7. In addition, four different cellular populations (SP/CD133(+), SP/CD133(-), non-SP/CD133(+), and non-SP/CD133(-)) could similarly produce CD133(+) and CD133(-) cells during subculture. CONCLUSION: This study revealed that CD133 could be a biliary and progenitor cell marker in vivo. However, CD133 alone is not sufficient to detect tumor-initiating cells in cell lines.
Authors: Tania A Roskams; Neil D Theise; Charles Balabaud; Govind Bhagat; Prithi S Bhathal; Paulette Bioulac-Sage; Elizabeth M Brunt; James M Crawford; Heather A Crosby; Valeer Desmet; Milton J Finegold; Stephen A Geller; Annette S H Gouw; Prodromos Hytiroglou; A S Knisely; Masamichi Kojiro; Jay H Lefkowitch; Yasuni Nakanuma; John K Olynyk; Young Nyun Park; Bernard Portmann; Romil Saxena; Peter J Scheuer; Alastair J Strain; Swan N Thung; Ian R Wanless; A Brian West Journal: Hepatology Date: 2004-06 Impact factor: 17.425
Authors: N D Theise; R Saxena; B C Portmann; S N Thung; H Yee; L Chiriboga; A Kumar; J M Crawford Journal: Hepatology Date: 1999-12 Impact factor: 17.425
Authors: Satish K Tickoo; Sui Y Zee; Sam Obiekwe; Hong Xiao; Jonathan Koea; Christian Robiou; Leslie H Blumgart; William Jarnagin; Marc Ladanyi; David S Klimstra Journal: Am J Surg Pathol Date: 2002-08 Impact factor: 6.394
Authors: Gavin D Richardson; Craig N Robson; Shona H Lang; David E Neal; Norman J Maitland; Anne T Collins Journal: J Cell Sci Date: 2004-06-29 Impact factor: 5.285
Authors: Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: Sergey V Shmelkov; Jason M Butler; Andrea T Hooper; Adilia Hormigo; Jared Kushner; Till Milde; Ryan St Clair; Muhamed Baljevic; Ian White; David K Jin; Amy Chadburn; Andrew J Murphy; David M Valenzuela; Nicholas W Gale; Gavin Thurston; George D Yancopoulos; Michael D'Angelica; Nancy Kemeny; David Lyden; Shahin Rafii Journal: J Clin Invest Date: 2008-06 Impact factor: 14.808
Authors: T Wang; H S Hu; Y X Feng; J Shi; N Li; W X Guo; J Xue; D Xie; S R Liu; M C Wu; S Q Cheng Journal: Br J Cancer Date: 2010-05-11 Impact factor: 7.640
Authors: George S Wilson; Zenan Hu; Wei Duan; Aiping Tian; Xin M Wang; Duncan McLeod; Vincent Lam; Jacob George; Liang Qiao Journal: Stem Cells Dev Date: 2013-06-08 Impact factor: 3.272
Authors: Maurizio Romano; Francesco De Francesco; Giuseppe Pirozzi; Enrico Gringeri; Riccardo Boetto; Marina Di Domenico; Barbara Zavan; Giuseppe A Ferraro; Umberto Cillo Journal: Oncoscience Date: 2015-05-15
Authors: Mohammed Saeed Rozeik; Olfat Ali Hammam; Ali Ibrahim Ali; Mona Magdy; Heba Khalil; Amgad Anas; Ahmed Abdelaleem Abo El Hassan; Ali Abdel Rahim; Ahmed Ibrahim El-Shabasy Journal: Electron Physician Date: 2017-07-25